×
About 1,943 results

ALLMedicine™ Lennox-gastaut Syndrome Center

Research & Reviews  292 results

Epidiolex plus THC lowers seizures in pediatric epilepsy
https://www.mdedge.com/neurology/article/247341/epilepsy-seizures/epidiolex-plus-thc-lowers-seizures-pediatric-epilepsy
Randy Dotinga

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

Severe autonomic nervous system imbalance in Lennox-Gastaut syndrome patients demonstra...
https://doi.org/10.1016/j.eplepsyres.2021.106783
Epilepsy Research; Hödl S, Olbert E et. al.

Oct 10th, 2021 - Patients diagnosed with Lennox Gastaut syndrome (LGS), an epileptic encephalopathy characterized by usually drug resistant generalized and focal seizures, are often considered as candidates for vagus nerve stimulation (VNS). Recent research shows ...

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
https://clinicaltrials.gov/ct2/show/NCT03731715

Oct 7th, 2021 - A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer a...

EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome.
https://clinicaltrials.gov/ct2/show/NCT05066217

Oct 4th, 2021 - To evaluate the efficacy of EPX-100 orally in divided doses as adjunctive therapy compared with placebo as measured by percent change in the frequency of seizures that result in drops in participants with Lennox-Gastaut Syndrome between the 4-week...

Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: ...
https://doi.org/10.1016/j.yebeh.2021.108275
Epilepsy & Behavior : E&B; Arzimanoglou A, Pringsheim M et. al.

Sep 13th, 2021 - Lennox-Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy with the first symptoms usually appearing during early childhood. Due to the highly variable underlying etiologies, LGS cannot be considered as one disease but as an ele...

see more →

Drugs  401 results see all →

Clinicaltrials.gov  8 results

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
https://clinicaltrials.gov/ct2/show/NCT03731715

Oct 7th, 2021 - A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years), Cohort II (12 to <18 years), Cohort III (6 to <12 years), and Cohort IV (2 to <6 years). For Cohorts I and II, PK assessments of carisbamate, S-enantiomer a...

EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome.
https://clinicaltrials.gov/ct2/show/NCT05066217

Oct 4th, 2021 - To evaluate the efficacy of EPX-100 orally in divided doses as adjunctive therapy compared with placebo as measured by percent change in the frequency of seizures that result in drops in participants with Lennox-Gastaut Syndrome between the 4-week...

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
https://clinicaltrials.gov/ct2/show/NCT02175173

Aug 3rd, 2021 - This surveillance's objectives are Unknown adverse reactions Incidences of adverse drug reaction Efficacy during long-term administration Factors considered to have effect to safety and effectiveness Incidences of status epileptics, skin disorders...

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy
https://clinicaltrials.gov/ct2/show/NCT02815540

Feb 12th, 2021 - Specific Aims/Study Objectives This is a pilot study to explore the effects of cannabidiol (CBD) on autonomic cardiac function in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) when the CBD is administered as an artisanal oil....

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
https://clinicaltrials.gov/ct2/show/NCT01668654

Oct 30th, 2020 - Epilepsy is among the most common serious neurologic disorders in childhood. Medicines with novel actions of mechanisms of action are needed to try to address the unmet clinical need for seizure control in patients with treatment-resistant epileps...

see more →

News  76 results

Epidiolex plus THC lowers seizures in pediatric epilepsy
https://www.mdedge.com/neurology/article/247341/epilepsy-seizures/epidiolex-plus-thc-lowers-seizures-pediatric-epilepsy
Randy Dotinga

Oct 13th, 2021 - Children and young adults with epilepsy had fewer seizures after combination treatment with the drug Epidiolex, which contains the cannabidiol (CBD), and various doses of tetrahydrocannabinol (THC), the component of cannabis that makes people high.

CBD Gel a Promising Adjunct for Kids With Severe Epilepsy
https://www.medscape.com/viewarticle/958889

Sep 16th, 2021 - Topical cannabidiol (CBD) gel, added to antiseizure medication, may help reduce seizures and improve quality of life in children with developmental and epileptic encephalopathies, according to the results of a nonrandomized controlled trial. Devel...

Cannabidiol Cleared for Tuberous Sclerosis Complex in Europe
https://www.medscape.com/viewarticle/949596

Apr 20th, 2021 - The European Commission (EC) has approved cannabidiol (Epidyolex) oral solution as adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older. It's the third indication for the drug in Euro...

Cannabinoids 'Worth a Try' for Agitation in Alzheimer's
https://www.medscape.com/viewarticle/945163

Feb 2nd, 2021 - Tetrahydrocannabinol (THC), the psychoactive agent in cannabinoids, may provide an alternative to off-label use of antipsychotics and other medications to manage agitation in patients with Alzheimer's disease (AD), a new clinical review suggests. ...

Cannabidiol Gets FDA Nod for New Indication
https://www.medpagetoday.com/neurology/seizures/87864

Aug 3rd, 2020 - WASHINGTON -- Cannabidiol oral solution (Epidiolex) won approval for a new indication and can be used to treat seizures in patients with tuberous sclerosis complex (TSC) age 1 year and older, the FDA announced late Friday. Epidiolex is a pharmaceu...

see more →